Austar Lifesciences FY26 interim profit attributable to owners drops 66.15% to RMB 8.46 million; revenue rises 12.48% to RMB 744.48 million

• Austar Lifesciences posted revenue of RMB 744.48 million for the six months ended June 30, up 12.48%.
• Profit attributable to owners fell 66.15% to RMB 8.46 million; basic earnings per share dropped to RMB 0.02 from RMB 0.05.
• Gross profit margin narrowed 2.4 percentage points to 18.6%, while gross profit edged down to RMB 138.15 million.
• Total order-in-take declined 19.9% to RMB 834.42 million, as management became more selective on project margin and payment terms.
• Backlog at June 30 totaled RMB 1.16 billion across 1,623 contracts, led by Integrated Process and Packaging Equipment & Systems at RMB 615.49 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Austar Lifesciences Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260825-12298796), on August 25, 2026, and is solely responsible for the information contained therein.